Last reviewed · How we verify

Long Neck Medical Enterprises — Portfolio Competitive Intelligence Brief

Long Neck Medical Enterprises pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Astellas Pharma Global Development, Inc. · 1 shared drug class
  2. Barbara Ensoli, MD · 1 shared drug class
  3. Bharat Biotech International Limited · 1 shared drug class
  4. Chiang Mai University · 1 shared drug class
  5. Clinical Research Organization, Dhaka, Bangladesh · 1 shared drug class
  6. Cytos Biotechnology AG · 1 shared drug class
  7. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Long Neck Medical Enterprises:

Cite this brief

Drug Landscape (2026). Long Neck Medical Enterprises — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/long-neck-medical-enterprises. Accessed 2026-05-16.

Related